• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Personalis Inc.

    5/6/25 4:12:22 PM ET
    $PSNL
    Medical Specialities
    Health Care
    Get the next $PSNL alert in real time by email
    8-K
    false 0001527753 0001527753 2025-05-06 2025-05-06
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 6, 2025

     

     

    Personalis, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

     

    Delaware   001-38943   27-5411038

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    6600 Dumbarton Circle

    Fremont, California

      94555
    (Address of Principal Executive Offices)   (Zip Code)

    (650) 752-1300

    Registrant’s Telephone Number, Including Area Code

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

     

      ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

      ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

      ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

      ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Common Stock, $0.0001 par value per share   PSNL   The Nasdaq Global Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 2.02

    Results of Operations and Financial Condition.

    On May 6, 2025, Personalis, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference.

    The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

     

    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit

    Number

      

    Description

    99.1    Press release of Personalis, Inc., dated May 6, 2025.
    104    Cover Page Interactive Data File (embedded within the inline XBRL document)


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

    Date: May 6, 2025   Personalis, Inc.
        By:  

    /s/ Aaron Tachibana

          Aaron Tachibana
          Chief Financial Officer and Chief Operating Officer
    Get the next $PSNL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PSNL

    DatePrice TargetRatingAnalyst
    5/15/2025$6.00Buy
    Guggenheim
    3/17/2025$8.00Buy
    Canaccord Genuity
    2/6/2023$8.00Hold → Buy
    Needham
    2/6/2023Hold → Buy
    Needham
    2/25/2022$30.00 → $24.00Outperform
    Oppenheimer
    2/25/2022$30.00 → $18.00Buy
    Citigroup
    2/25/2022$50.00 → $38.00Buy
    HC Wainwright & Co.
    1/7/2022$27.00 → $23.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $PSNL
    SEC Filings

    See more
    • Personalis Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Personalis, Inc. (0001527753) (Filer)

      5/19/25 4:10:07 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Personalis Inc.

      SCHEDULE 13G/A - Personalis, Inc. (0001527753) (Subject)

      5/14/25 10:39:48 AM ET
      $PSNL
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by Personalis Inc.

      10-Q - Personalis, Inc. (0001527753) (Filer)

      5/6/25 4:24:12 PM ET
      $PSNL
      Medical Specialities
      Health Care

    $PSNL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO

      Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new results from the CALLA phase 3 study showing for the first time its ultrasensitive NeXT Personal circulating tumor DNA (ctDNA) blood test detected cervical cancer progression, up to 16 months ahead of imaging. The results demonstrate the potential of NeXT Personal to enable earlier detection in a cancer with high recurrence rates. The results were presented yesterday by Jyoti Mayadev, MD, from the University of California San Diego, at the American Society for Clinical Oncology (ASCO) 2025 Annual Meeting in Chicago in an oral presentation titled "Ultrasensitive detection

      6/3/25 4:00:00 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse

      Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new clinical results from the PREDICT DNA and SCANDARE studies highlighting the capabilities of its ultrasensitive NeXT Personal circulating tumor DNA (ctDNA) blood test for monitoring and predicting neoadjuvant therapy (NAT) response in triple negative breast cancer (TNBC), one of the most aggressive types of breast cancer. "Many triple negative breast cancer patients receive neoadjuvant therapy prior to surgery as standard of care. The data from these two studies independently suggest that an ultrasensitive ctDNA assay like NeXT Personal could help these patients better un

      6/2/25 4:00:00 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection

      Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced multiple presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting next week in Chicago, Illinois. The presentations feature new data from clinical studies utilizing the NeXT Personal® ultrasensitive ctDNA assay for residual and recurrent cancer detection. "These studies continue to expand the clinical data for NeXT Personal into new areas, including neoadjuvant treatment in breast cancer and cervical cancer," said Dr. Richard Chen, Chief Medical Officer and Executive Vice President, R&D at Personalis. "We continue to be driven by our mission to provide physicians and thei

      5/22/25 6:00:00 AM ET
      $PSNL
      Medical Specialities
      Health Care